NovaCure Diagnostics Expands Molecular Testing Network With New Advanced Laboratory in Texas
New facility strengthens molecular diagnostics capabilities, expands testing capacity and supports faster turnaround times for healthcare providers across the Southern United States
AUSTIN, Texas, July 14, 2026 — NovaCure Diagnostics, a provider of molecular diagnostic testing and laboratory solutions, today announced the opening of a new molecular diagnostics laboratory in Austin, Texas, expanding the company’s testing network and increasing access to advanced diagnostic services for healthcare providers throughout the Southern United States.
The facility represents the latest phase of NovaCure’s long-term growth strategy to increase laboratory capacity, strengthen operational efficiency and support the growing demand for precision medicine. Designed to serve hospitals, physician groups and healthcare systems, the laboratory will offer a broad portfolio of molecular testing services while helping reduce turnaround times for clinically significant results.
Expanding Access to Advanced Molecular Diagnostics
The Austin laboratory has been designed to perform a wide range of molecular diagnostic services, including infectious disease testing, oncology biomarker analysis, pharmacogenomics and hereditary genetic screening.
The facility combines next-generation sequencing (NGS) technology, automated specimen processing and digital laboratory workflows to improve operational consistency while supporting high-volume testing requirements.
NovaCure said the expanded capacity will help healthcare providers obtain timely laboratory information that supports clinical decision-making across multiple medical specialties.
Supporting the Growth of Precision Medicine
The expansion comes as healthcare organizations continue increasing their investment in molecular diagnostics to support personalized treatment planning, earlier disease detection and more targeted clinical care.
Advances in genomic technologies, laboratory automation and digital pathology continue to reshape diagnostic medicine by improving efficiency and enabling laboratories to process increasingly complex testing workflows. These technologies are also helping laboratories deliver more standardized results while supporting growing testing volumes.
Built Around Quality, Compliance and Laboratory Efficiency
According to NovaCure Diagnostics, the Austin laboratory was developed with a strong emphasis on quality assurance, regulatory compliance and operational reliability.
The facility incorporates automated specimen tracking, digital workflow management and technology-assisted quality monitoring that enables laboratory teams to oversee testing performance throughout every stage of the diagnostic process.
Rather than replacing scientific expertise, these systems are intended to streamline routine laboratory operations and allow qualified professionals to focus on clinical interpretation and quality assurance.
The laboratory also includes dedicated departments for molecular biology, clinical genomics, microbiology and bioinformatics, allowing multiple testing disciplines to operate within a centralized environment while maintaining standardized quality management procedures.
Strengthening Regional Healthcare Partnerships
NovaCure said it plans to expand collaboration with hospitals, specialty clinics, physician networks and academic medical centers throughout Texas, Oklahoma, Louisiana, Arkansas and New Mexico.
These partnerships are expected to improve access to specialized molecular testing while supporting healthcare providers with timely laboratory reporting and consultative expertise.
The company also plans to introduce additional testing panels focused on infectious diseases, oncology and inherited genetic disorders as demand for precision diagnostics continues to grow.
Executive Perspective
“Healthcare providers depend on timely, reliable diagnostic information to make informed clinical decisions,” said Dr. Laura Bennett, chief executive officer of NovaCure Diagnostics.
“Our continued investment in laboratory infrastructure reflects the growing role molecular diagnostics play in modern healthcare. By combining experienced laboratory professionals with advanced automation and standardized workflows, we aim to strengthen testing capacity while maintaining the quality and consistency healthcare providers expect.”
Looking Ahead
The Austin laboratory is expected to begin accepting clinical specimens later this month following completion of final operational validation procedures.
NovaCure said future investments will focus on expanding molecular testing capabilities, strengthening laboratory informatics and supporting healthcare providers with scalable diagnostic solutions as demand for precision medicine continues to evolve.
About NovaCure Diagnostics
NovaCure Diagnostics is a privately held clinical laboratory company specializing in molecular diagnostics, genomic testing and laboratory informatics solutions. The company partners with hospitals, physician practices, healthcare systems and research organizations to deliver advanced diagnostic services that support precision medicine and evidence-based clinical care across North America.
Website: www.novacurediagnostics.com
Media Contact
Rachel Morgan
Director of Corporate Communications
NovaCure Diagnostics
Email: [email protected]
Phone: +1 (512) 555-0184